Global Health Limited
Global Health Limited, together with its subsidiaries, provides healthcare services in India. The company offers treatments in the areas of digestive and hepatobiliary sciences, cardiac and cancer care, neurosciences, gastrosciences, orthopaedics, renal care, liver transplant, lung transplant, bone marrow transplant, chest surgery, gynaecology and gynaeoncology, paediatric care, obstetrics, emergency, ENT, head and neck surgery, internal medicine, respiratory and sleep medicine, peripheral vascular and endovascular sciences, endocrinology and diabetes, rheumatology and immunology, radiology and imaging, ophthalmology, critical care, dermatology, dentistry, and dietetics and nutrition, as well as plastic, aesthetic, and reconstructive surgery. It also provides second opinion, lab tests and diagnostics, homecare and elder care services, telemedicine and air ambulance services, and e-ICU services, and health plans checkup. In addition, the company is involved in trading of pharmacy and other medical consumables; and medical and healthcare education activities. The company operates a network of hospitals under the Medanta brand. Global Health Limited was incorporated in 2004 and is based in Gurugram, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockRule-based from financial data. Not advice.
Historically, Feb has averaged the highest return (+13.5%); Sep the lowest (-4.4%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -11.0%Negative MonthJan 2026: -11.04% | +8.1%Positive MonthFeb 2026: +8.14% | -15.7%Negative MonthMar 2026: -15.71% | +16.2%Positive MonthApr 2026: +16.21% | +10.8%Positive MonthMay 2026: +10.81% | +6.1%Positive MonthJun 2026: +6.14% | +6.3%*Positive MonthJul 2026: +6.35% | β | β | β | β | β |
| 2025 | -3.3%Negative MonthJan 2025: -3.33% | +10.2%Positive MonthFeb 2025: +10.20% | +4.2%Positive MonthMar 2025: +4.21% | +0.0%Neutral MonthApr 2025: +0.02% | -0.9%Neutral MonthMay 2025: -0.91% | -4.1%Negative MonthJun 2025: -4.05% | +15.0%Positive MonthJul 2025: +15.04% | +4.9%Positive MonthAug 2025: +4.86% | -4.4%Negative MonthSep 2025: -4.45% | +0.0%Neutral MonthOct 2025: +0.04% | -5.2%Negative MonthNov 2025: -5.20% | -4.8%Negative MonthDec 2025: -4.79% |
| 2024 | +19.7%Positive MonthJan 2024: +19.73% | +18.9%Positive MonthFeb 2024: +18.86% | -3.0%Negative MonthMar 2024: -2.98% | +9.2%Positive MonthApr 2024: +9.16% | -17.4%Negative MonthMay 2024: -17.44% | +9.5%Positive MonthJun 2024: +9.54% | -5.1%Negative MonthJul 2024: -5.09% | -8.6%Negative MonthAug 2024: -8.58% | -9.4%Negative MonthSep 2024: -9.38% | +7.6%Positive MonthOct 2024: +7.61% | -2.7%Negative MonthNov 2024: -2.75% | +0.4%Neutral MonthDec 2024: +0.37% |
| 2023 | -4.9%Negative MonthJan 2023: -4.92% | +16.9%Positive MonthFeb 2023: +16.91% | +1.1%Neutral MonthMar 2023: +1.12% | -2.2%Negative MonthApr 2023: -2.17% | +15.3%Positive MonthMay 2023: +15.26% | +11.2%Positive MonthJun 2023: +11.18% | +6.8%Positive MonthJul 2023: +6.75% | +0.9%Neutral MonthAug 2023: +0.85% | +0.7%Neutral MonthSep 2023: +0.75% | +9.7%Positive MonthOct 2023: +9.65% | +22.3%Positive MonthNov 2023: +22.34% | -0.1%Neutral MonthDec 2023: -0.11% |
| 2022 | β | β | β | β | β | β | β | β | β | β | β | +1.1%Neutral MonthDec 2022: +1.11% |
| AvgΒ±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position β all Januaries together, all Februaries together, and so on β to show whether a given month has leaned positive or negative historically. βSimpleβ counts each month as +1 or β1. βWeightedβ gives larger moves more influence: +2 above +10%, β2 below β10%. With only 5 years of history for this asset, each monthβs score reflects a small number of observations β read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the assetβs full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each dayβs closing price by the price on January 1st of that year (or the assetβs first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in βAverage fromβ, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ3.20 K Cr | β | βΉ462.00 Cr | β | β | 13.2% | 7.7% | -4.9% |
| Mar 2024 | βΉ2.98 K Cr | β | βΉ486.00 Cr | β | β | 16.0% | 50.7% | 84.8% |
| Mar 2023 | βΉ1.97 K Cr | β | βΉ263.00 Cr | β | β | 10.6% | 11.8% | 20.1% |
| Mar 2022 | βΉ1.76 K Cr | β | βΉ219.00 Cr | β | β | 12.6% | 43.8% | 284.2% |
| Mar 2021 | βΉ1.23 K Cr | β | βΉ57.00 Cr | β | β | 3.8% | -16.6% | -44.7% |
| Mar 2020 | βΉ1.47 K Cr | β | βΉ103.00 Cr | β | β | 7.4% | 2.2% | 63.5% |
| Mar 2019 | βΉ1.44 K Cr | β | βΉ63.00 Cr | β | β | 4.9% | 7.3% | 70.3% |
| Mar 2018 | βΉ1.34 K Cr | β | βΉ37.00 Cr | β | β | 3.1% | 5.2% | -31.5% |
| Mar 2017 | βΉ1.28 K Cr | β | βΉ54.00 Cr | β | β | 4.8% | β | β |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Net Sales | 1,277 | 1,343 | 1,441 | 1,472 | 1,227 | 1,765 | 1,974 | 2,975 | 3,204 | 3,424 |
| Total Expenses | 1,158 | 1,218 | 1,297 | 1,253 | 1,054 | 1,384 | 1,551 | 2,222 | 2,432 | 2,640 |
| EBIT / Operating Profit | 119 | 125 | 144 | 219 | 173 | 381 | 423 | 753 | 772 | 784 |
| OPM % | 9% | 9% | 10% | 15% | 14% | 22% | 21% | 25% | 24% | 23% |
| Other Income | 67 | 49 | 64 | 43 | 28 | 35 | 47 | 91 | 41 | 77 |
| Finance Costs | 19 | 24 | 21 | 33 | 29 | 33 | 32 | 51 | 41 | 30 |
| Depreciation & Amortisation | 77 | 86 | 91 | 99 | 88 | 87 | 86 | 134 | 150 | 146 |
| Profit Before Tax | 89 | 64 | 97 | 131 | 84 | 296 | 352 | 659 | 623 | 684 |
| Tax % | 39% | 42% | 35% | 22% | 32% | 26% | 25% | 26% | 26% | - |
| Net Profit / PAT | 54 | 37 | 63 | 103 | 57 | 219 | 263 | 486 | 462 | 517 |
| EPS (βΉ) | 11.21 | 7.70 | 12.81 | 20.82 | 11.55 | 8.64 | 9.82 | 18.11 | 17.18 | 19.24 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Global Health Limitedthis co. | βΉ31.40 K Cr | βΉ3.20 K Cr | 59.80 | 8.28 | 37.31 | 7.7% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |
